- National Resilience announced it was approved for $410 million in financing.
National Resilience (Resilience), a technology-focused biomanufacturing company focused on broadening access to complex medicines announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD), working with the U.S. International Development Finance Corporation (DFC). This loan financing will support Resilience’s mission to set up a significant domestic, end-to-end biomanufacturing capacity and capabilities for biologics (antibodies, proteins, multi-specifics), vaccines, and nucleic acids (including mRNA).
Plus this expanded capacity – together with existing technology and capabilities across Resilience’s biomanufacturing network – will help secure the nation’s supply chain for vaccines and critical medicines, bolster pandemic preparedness and response along with helping address a critical advanced manufacturing infrastructure shortage revealed by the COVID-19 pandemic. And part of the funding will support the implementation of innovative manufacturing platforms and technologies that aim to reduce cost, strengthen domestic supply chains, and increase vaccine supply speed.
The long-term funding also strengthens Resilience’s ability to deliver the highest quality products to patients and to the 50-plus commercial customers that utilize its nearly 2 million square feet of end-to-end drug development capacity and solutions that span process and analytical development and GMP biomanufacturing across multiple therapeutic modalities. And with this support, Resilience will be able to manufacture a billion doses of vaccines within its manufacturing network in the United States and will continue to partner with biotech and biopharma innovators across the drug development life cycle.
KEY QUOTE:
“The lack of growth and innovation in domestic biomanufacturing was one critical vulnerability that impacted preparedness during the COVID-19 pandemic. This partnership is one of the many ways we are developing a more vibrant biopharmaceutical manufacturing ecosystem to keep pace with new scientific advancements and produce novel, safe, life-saving discoveries quickly and at scale to benefit the nation. Resilience is honored to partner with the DFC, DoD, and the U.S. government to ensure this country can maintain its innovative, competitive edge in biotechnology and biomanufacturing, while generating significant benefits to the health, security, and quality of American lives and those around the world.”
— Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience
